HIMS
Verified Company Hub
Real-Time Market Data
$29.76
-4.03%Latest AI Analysis
Analyst Verdict
["Hims & Hers demonstrated robust financial performance in 2025, with revenue soaring by 59% and Adjusted EBITDA increasing by 80%, indicating a healthy and expanding core business.","A game-changing partnership with Novo Nordisk announced on March 9, 2026, resolves significant regulatory overhangs concerning compounded GLP-1s and creates a substantial new revenue stream, removing a major investment risk.","The company is strategically diversifying its offerings into high-growth areas like menopause, longevity, and diagnostics, alongside aggressive international expansion via acquisitions like Eucalyptus.","Operating within a telehealth market projected to grow at a 24.73% CAGR through 2035, Hims & Hers now presents an increasingly attractive forward valuation (under 20x 2026 P/E) following the recent positive catalyst."]
THE BULL CASE
The Novo Nordisk agreement de-risks Hims' core growth engine in weight loss while simultaneously opening up massive new revenue channels, paving the way for sustained, accelerated subscriber and EPS expansion. Strategic international acquisitions and new health verticals will further amplify this growth, leading to significant multiple expansion in a robust telehealth market.
THE BEAR CASE
Despite the Novo Nordisk deal, intense competition in the rapidly evolving telehealth space and potential future regulatory shifts could pressure margins and limit market share gains. Furthermore, a slowdown in subscriber growth or challenges in integrating new acquisitions could undermine ambitious long-term targets, leading to a de-rating.